Business
Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma
DALLAS, Dec. 17, 2020 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence
About this update from Lantern Pharma Inc.
[{"type":"text","content":"DALLAS, Dec. 17, 2020 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence (\"A.I.\") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced a collaboration and research agreement with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Kennedy Krieger Institute. The collaboration will focus on the further development of Lantern's LP-184 in glioblastoma multiforme (GBM). Based in Baltimore, Johns Hopkins is a leading research center for brain cancers and one of the largest brain tumor treatment and research centers in the world with a focus on treating an extremely large number of patients affected by all types of brain tumors. \n\n \n \n \n \n \n \n\n \nThe collaboration will focus on advancing the targeted use of LP-184 in defined subtypes of GBM and clarifying the most promising clinical applications for the drug candidate. The goal of the collaboration is to develop a clinically ready program that has characterized the drug candidate with the most biologically relevant and robust genomic or biomarker signature. By having a gene signature that can be used in identifying patients that have the potential for the highest response, Lantern can potentially accelerate future clinical trials and shorten the time to achieving patient benefit for GBM patients. \nThe research program is at the forefront of translational cancer medicine and will use patient-derived cancer cells that are studied using physiologically relevant in vitro and in vivo models. This innovative approach allows researchers to more precisely understand the biology of what actually happens inside the cancer tumor, which will more accurately establish the precise biomarker signatures and help provide data-driven insight into additional mechanisms that can be leveraged in the fight against brain cancer.\n\"Collaborations with world-leading cancer centers are an essential part of our strategy to rapidly advance the insights driving our therapeutic programs and grow the power of our RADR® A.I. platform by adding millions of new, unique, and proprietary data points in areas of high unmet need in cancer,\" said Panna Sharma, CEO of Lantern Pharma. \"This relationship with Johns Hopkins is expec...